Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• Prestige Consumer Healthcare Inc. has received a consensus rating of "Hold" from analysts, with one sell recommendation, three holds, and three buy ratings.
• The company's latest quarterly earnings showed an EPS of $0.95, missing analysts' expectations of $1.01, and revenue declined by 6.6% compared to the previous year.
• Prestige Consumer Healthcare's average target price among brokers is $93.33, despite recent downgrades from various research firms.

Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) has received a consensus rating of "Hold" from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $93.3333.

Several research firms have recently commented on PBH. Canaccord Genuity Group decreased their price objective on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Wall Street Zen lowered Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Finally, Zacks Research downgraded Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a research report on Thursday, September 4th.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its position in shares of Prestige Consumer Healthcare by 35.9% in the first quarter. GAMMA Investing LLC now owns 1,879 shares of the company's stock valued at $162,000 after acquiring an additional 496 shares during the period. KBC Group NV grew its stake in shares of Prestige Consumer Healthcare by 7.4% in the first quarter. KBC Group NV now owns 2,199 shares of the company's stock worth $189,000 after purchasing an additional 151 shares during the last quarter. QRG Capital Management Inc. increased its holdings in Prestige Consumer Healthcare by 8.6% during the 1st quarter. QRG Capital Management Inc. now owns 5,971 shares of the company's stock valued at $513,000 after purchasing an additional 475 shares during the period. Wealth Enhancement Advisory Services LLC raised its position in Prestige Consumer Healthcare by 14.1% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 8,315 shares of the company's stock valued at $649,000 after purchasing an additional 1,030 shares during the last quarter. Finally, XTX Topco Ltd raised its position in Prestige Consumer Healthcare by 354.0% during the 1st quarter. XTX Topco Ltd now owns 22,778 shares of the company's stock valued at $1,958,000 after purchasing an additional 17,761 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Trading Up 0.3%

Shares of PBH opened at $65.98 on Wednesday. Prestige Consumer Healthcare has a fifty-two week low of $62.95 and a fifty-two week high of $90.04. The firm has a market cap of $3.25 billion, a price-to-earnings ratio of 15.49, a PEG ratio of 2.08 and a beta of 0.46. The firm has a 50 day moving average price of $71.47 and a 200-day moving average price of $79.63. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.95 EPS for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). The business had revenue of $249.53 million during the quarter, compared to analysts' expectations of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.Prestige Consumer Healthcare's revenue for the quarter was down 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. As a group, equities research analysts forecast that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.